Carisma Therapeutics, Inc.
CARM
$0.2153
$0.00180.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 15.86% | 40.65% | 43.84% | 22.99% | -25.20% |
| Total Depreciation and Amortization | -7.34% | 6.04% | -64.34% | 140.14% | 2.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | -70.38% | -1.42% | 187.59% | 74.81% | 13.27% |
| Change in Net Operating Assets | 283.11% | -30.60% | -1,197.54% | -77.19% | 161.16% |
| Cash from Operations | 48.11% | 38.00% | 13.09% | 12.18% | 5.87% |
| Capital Expenditure | 100.00% | 100.00% | 57.09% | 87.41% | -75.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -22.14% |
| Cash from Investing | -100.00% | -100.00% | -100.30% | 99.53% | -24.40% |
| Total Debt Issued | -- | -100.00% | 100.00% | -37.18% | -100.00% |
| Total Debt Repaid | -1.02% | 60.08% | 147.33% | -974.17% | -302.04% |
| Issuance of Common Stock | -- | 222.50% | -96.15% | -92.53% | 3,744.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -713.86% | 77.32% | 102.01% | -98.00% | 106.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.45% | -298.86% | -218.98% | -154.62% | -17.01% |